Show simple item record

dc.contributor.authorTrevisan França de Lima, L
dc.contributor.authorBroszczak, D
dc.contributor.authorZhang, X
dc.contributor.authorBridle, K
dc.contributor.authorCrawford, D
dc.contributor.authorPunyadeera, C
dc.date.accessioned2021-11-17T22:20:15Z
dc.date.available2021-11-17T22:20:15Z
dc.date.issued2020
dc.identifier.issn0304-419Xen_US
dc.identifier.doi10.1016/j.bbcan.2020.188451en_US
dc.identifier.urihttp://hdl.handle.net/10072/410191
dc.description.abstractHepatocellular carcinoma (HCC) is a common cause of cancer-related deaths worldwide. Despite advances in systemic therapies, patient survival remains low due to late diagnosis and frequent underlying liver diseases. HCC diagnosis generally relies on imaging and liver tissue biopsy. Liver biopsy presents limitations because it is invasive, potentially risky for patients and it frequently misrepresents tumour heterogeneity. Recently, liquid biopsy has emerged as a way to monitor cancer progression in a non-invasive manner. Tumours shed content into the bloodstream, such as circulating tumour cells (CTCs), circulating nucleic acids, extracellular vesicles and proteins, that can be isolated from biological fluids of patients with HCC. These biomarkers provide knowledge regarding the genetic landscape of tumours and might be used for diagnostic or prognostic purposes. In this review, we summarize recent literature on circulating biomarkers for HCC, namely CTCs, circulating tumour DNA (ctDNA), RNA, extracellular vesicles and proteins, and their clinical relevance in HCC.en_US
dc.languageengen_US
dc.publisherElsevier BVen_US
dc.relation.ispartofpagefrom188451en_US
dc.relation.ispartofissue2en_US
dc.relation.ispartofjournalBiochimica et Biophysica Acta - Reviews on Canceren_US
dc.relation.ispartofvolume1874en_US
dc.subject.keywordsBiomarkeren_US
dc.subject.keywordsCirculating tumor DNA (ctDNA)en_US
dc.subject.keywordsCirculating tumor cells (CTCs)en_US
dc.subject.keywordsHepatocellular carcinomaen_US
dc.subject.keywordsLiquid biopsyen_US
dc.titleThe use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinomaen_US
dc.typeJournal articleen_US
dcterms.bibliographicCitationTrevisan França de Lima, L; Broszczak, D; Zhang, X; Bridle, K; Crawford, D; Punyadeera, C, The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma, Biochimica et Biophysica Acta - Reviews on Cancer, 2020, 1874 (2), pp. 188451en_US
dcterms.dateAccepted2020-10-08
dcterms.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.date.updated2021-11-17T22:15:53Z
dc.description.versionAccepted Manuscript (AM)en_US
gro.rights.copyright© 2020 Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.en_US
gro.hasfulltextFull Text
gro.griffith.authorPunyadeera, Chamindie


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record